AstraZeneca Stock News

AstraZeneca PLC (LSE:AZN) shares spiked higher on Tuesday afternoon on reports that the boss of the UK pharmaceutical giant wants to move the company to the US. CEO Pascal Soriot wants to the FTSE 100's largest company to leave the UK due to his frustration with restrictions on medicines and pricing under the NHS, according to a report in The Times.

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United States, The Times reported on Tuesday, citing multiple sources.

AstraZeneca's price performance YTD exceeds the healthcare sector and broader markets, indicating investors are assuaged regarding concerns across geographies. The company has offered greater clarity on why its under investigation in China, and so far there's reason to believe matters are under control. US tariffs are unlikely to affect its financials significantly in 2025 either, with the comp...

UBS has maintained its 'buy' recommendation on AstraZeneca PLC (LSE:AZN), setting a 12-month price target of 10,121p, reflecting confidence that a wave of late-stage clinical readouts will provide fresh share-price catalysts after a period dominated by patent expiries and pricing headwinds. Stepping into the third quarter of 2025, AstraZeneca faces what UBS describes as “a busy quarter” of pivo...

What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), has received a formal Expression of Interest (EOI) from AstraZeneca plc (AstraZeneca), indicating its intent to participate as a founding member in the Predictive ...

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work?

AstraZeneca PLC (LSE:AZN) has scored another significant milestone in its cancer treatment programme, securing accelerated approval from the US Food and Drug Administration (FDA) for Datroway, a promising drug aimed at treating advanced lung cancer. According to analysts at Shore Capital, this marks a notable step forward, even though the approval initially targets a smaller patient group than ...